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Abstract
!
This review discusses successful strategies and
potential pitfalls to assembling a natural prod-
uct-based library suitable for high-throughput
screening. Specific extraction methods for plants,
microorganisms, and marine invertebrates are
detailed, along with methods for generating a
fractionated sub-library. The best methods to
store, maintain and prepare the library for screen-
ing are addressed, as well as recommendations on
how to develop a robust high-throughput assay.
Finally, the logistics of moving from an assay hit
to pure bioactive compound are discussed.
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.Introduction
!
Natural products often possess biological activity
and are a valuable source of drug leads [1–4].
Many natural products occupy unique areas of
chemical space [5] and they often differ from syn-
thetic compounds by the presence of multiple
chiral centers, an abundance of O over N atoms,
and more H-bond donors and acceptors [6–9].
Despite these structural differences and rich his-
tory in drug development, natural product-based
hit discovery is currently almost nonexistent in
large pharmaceutical companies. This is mainly
due to the perception that (i) the time between
isolation and structure elucidation is too long, (ii)
there are diminishing returns due to high derepli-
cation rates, (iii) there is a resupply issue for hit-
to-lead and preclinical studies, and (iv) natural
products are not “drug-like” and make poor leads.
These perceptions can be countered as follows.
Advances in dereplication, isolation techniques,
and structure elucidation have reduced the time
from extract to pure compound to under one
month on average in well equipped, organized,
and experienced labs [1,10,11]. The resupply is-
sue can be resolved by focusing on microorgan-
isms, with other organism types such as marine
invertebrates and plants only screened if there is
well documented collection information and a re-
supply plan. Advances in synthesis have also
solved some supply issues as demonstrated by
the totally synthetic anticancer drug eribulin
mesylate (trade name: Halaven®; launched 2010)Butler MS et al. Nthat was derived from the complex, sponge-de-
rived lead halichondrin B (l" Fig. 1) [12,13]. Natu-
ral product anticancer drugs such as trabectedin
(trade name: Yondelis®; launched in 2007) [14,
15] and homoharringtonine (trade name: Synri-
bo®; launched 2012) [16] are produced semisyn-
thetically for clinical use to overcome resupply
issues (l" Fig. 1).
The concern that natural products are “drug-like”
is paradoxical given that natural products have
been lead structures for many drugs [2,4]. Chris-
topher Lipinski, who introduced the “rule-of-five”
for guiding drug-like properties required for oral
adsorption, suggested that these rules were not
suitable for natural products due to the potential
for active transport [17]. The disconnect with the
rule-of-five and some natural products is demon-
strated in Ganesanʼs analysis of the 24 natural
product drug leads discovered from 1970–2006
that led to a drug approval [18]. In this study, it
was found that half of these leads were inside the
“Lipinski universe” (0 or 1 rule violations) chemi-
cal space, while the other half were in a natural
product “parallel universe”. Revealingly, leads
from the “parallel universe” had an equivalent
chance to leads from the “Lipinski universe” of
producing an oral drug; these leads were Lipin-
ski-compliant in terms of clogP and H-bond do-
nors, as well as potentially being able to access
carrier mediated or active transport mechanisms
[18].
In the 1980s, advances in robotics and computing,
coupled with enhanced access to biological re-atural Product Libraries:… Planta Med 2014; 80: 1161–1170
Fig. 1 Structures of the complex, sponge-derived
anticancer lead halichondrin B and its synthetically
inspired drug eribulin produced by total synthesis;
ester hydrolysis of the naturally occurring ester
mixture to give cephalotaxine, which is then esteri-
fied to give the anticancer drug homoharringtonine
(omacetaxine mepesuccinate); the ascidian-derived
anticancer drug trabectedin is semisynthetically
produced from the bacterial-derived cyanosafarin
B.
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.agents and proteins, enabled large pharmaceutical companies to
develop high-throughput screening (HTS) capabilities [19–21].
Initially HTS was used to screen modest sized synthetic com-
pound libraries (thousands of compounds) and natural product
extract libraries, but the increased screening capacity created
soon led to an explosion in the number of synthetic compounds
added to screening libraries using combinatorial chemistry (hun-
dreds of thousands of compounds). During this time, HTS has had
an impact on drug discovery leading to the identification of nu-
merous new drugs leads and at least 12 drugs on themarket [22].
For over 20 years, HTS facilities have also been used in academic
settings and smaller biotechnology companies to screen for new
drugs leads. As large pharmaceutical companies retreat further
from natural product-based lead discovery (and basic research),
there are now opportunities for university-based research
groups to be at the forefront of lead discovery in natural prod-
ucts. It is also now feasible for these groups to use in-house re-
sources and contract research organizations (CROs) to validate
these drug leads and undertake preclinical drug development
[23].
In this review, we discuss how to assemble a natural product-fo-
cused library that would consist of structurally diverse extracts,
prefractionated extracts, and pure compounds. Practical meth-
ods to maintain, store and efficiently screen these natural prod-
uct-derived samples are also discussed, as the logistics of moving
from an assay hit to pure bioactive compounds.Initiating a Natural Product Library
!
Extraction methods
The early years of natural product chemistry research were do-
minated by large scale plant-based studies that often used harsh
extraction methods. These extraction techniques included the
use of boiling solvents, acid-base extraction, and steam distilla-
tion. As isolation techniques and technology have improved, ex-
traction conditions have become milder, and the amount of com-
pound required for structure elucidation has dropped to well be-
low 1mg. Extraction methods [24,25] developed to increase ex-
traction efficiency include the use of ultrasound [26,27], micro-
wave [27,28], pressure (accelerated solvent extraction) [29],Butler MS et al. Natural Product Libraries:… Planta Med 2014; 80: 1161–1170supercritical fluid [30,31], ionic liquids [32], and deep eutectic
solvents [33,34]. Although these newer methods can be useful, a
simple method such as extraction with slightly aqueous MeOH
using gentle agitation captures most of the drug-like molecules
and is usually more than adequate for biological screening pur-
poses. Another popular extraction solvent for screening libraries
is EtOAc, which extracts less polar material compared to MeOH,
resulting in cleaner extracts of mid-polarity compounds. Extrac-
tion conditions for the compounds of interest can be subse-
quently optimized upon re-extraction or scale-up studies.
Sources of natural products
Plants: Plants have been used as the basis of medicines for thou-
sands of years and even today these traditional medicines are re-
lied upon for health care inmany parts of theworld [35,36]. Plant
secondary metabolites are often stored inside cells, which need
to be ruptured to increase the extractable yield. The plant mate-
rial is usually dried, either at slightly elevated temperatures or
using freeze drying, and ground to a fine powder before extrac-
tion. The choice of solvent depends upon the desired polarity
range with MeOH or EtOAc being excellent options for a single
solvent-derived extract library as previously discussed. Extracts
can also be generated by successively extracting with nonpolar
to polar solvents such as heptane, CH2Cl2, MeOH, and H2O, while
hot H2O can be used to mimic the administration of many tradi-
tional medicines as infused teas. Before screening, plant extracts
can be passed through a polyamide column (eluent MeOH) or
polyvinylpyrrolidone (PVP) to remove polyphenols that can in-
terfere with various enzyme biological assays [37–39]. Alkaloids
[40] can also be enriched from plant samples using an acid/base
extraction protocol and detected using Dragendorffʼs reagent
and/or using (+)-electrospray (ESI)-MS [37,41].
Microorganisms: Microbes have been the mainstay of industrially
focused natural product research due to their propensity to pro-
duce novel molecules and the use of fermentation as a renewable
source of compound resupply. Fungi and bacteria can be culti-
vated on both solid and liquid media under a variety of condi-
tions; however, bacteria are predominantly grown in liquid me-
dia, while fungi are grown using both solid and liquid media. Im-
portant parameters for secondary metabolite production are the
choice of media, temperature, aeration, and duration of the fer-
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.mentation. On a small scale, liquid cultivations can be performed
in test tubes, flasks, or specially designed microtiter plates [42–
44], which can be freeze-dried and extractedwith an appropriate
solvent or directly extracted with an organic solvent that is im-
miscible with the broth [e.g., EtOAc, n-butanol (n-BuOH), methyl
ethyl ketone (MEK), tert-butyl methyl ether (TBME)]. Centrifugal
evaporation is particularly useful for organisms grown in high
salt content media to minimize “bumping” that can occur during
freeze drying. For larger scale liquid cultivations, multiple flasks
or a bioreactor are used with the biomass usually separated from
the broth using centrifugation. The wet biomass can then be ex-
tracted directly, or freeze dried and then extracted. Broth metab-
olites can be concentrated by elution through a resin column
with increasing amounts of organic solvents (usually MeCN or
MeOH) in H2O. Commonly used resins are the brominated-poly-
styrene Sepabeads SP207 (Mitsubishi Chemical Corp), the cross-
linked polystyrene Diaion HP20 (Mitsubishi Chemical Corp), and
the XAD (The Dow Chemical Company) ion exchange resins.
These resins can also be added during cultivation to capture com-
pounds, often in increased yield, and to help with downstream
purification [45]. There have also been reports of larger scale sol-
id fermentations [46,47].
Altering media and cultivation conditions can considerably influ-
ence secondary metabolite profile production. This is exempli-
fied by the OSMAC (one strain many compounds) approach [48],
which is particularly compatible with the number of cultivations
available using the microtiter plate format, and the use of addi-
tives to alter secondary metabolite profiles [49–51] or activate
cryptic biosynthesis pathways [50,52,53].
Marine invertebrates: As a result of potential logistical difficulties
associated with marine invertebrate recollection, gentle extrac-
tion methods are generally used to minimize compound degra-
dation. A commonly used method is to cut the invertebrate in
smaller pieces, place in a plastic container, immerse in EtOH,
and refrigerate until required. EtOH is often used instead of
MeOH to try and distinguish between naturally occurring esters
and artifactual esterification. The Crews Group have reported a
method that they use in the field where specimens are immersed
in anMeOH:H2O (1:1) solution and after approximately 24 h the
liquid is decanted and discarded [54]. The specimen is placed in a
Nalgene container, shipped back to the laboratory at ambient
temperature and then stored at 4°C until further processed [54].
Marine invertebrate specimens can also be freeze dried, pow-
dered and extracted, but care needs to be taken as occasionally
some metabolites can sublime into the cold trap.
Prefractionation and purified NP libraries
One way to reduce the complexity of an extract is to fractionate
before biological testing using column-based [55–63] or liquid-
liquid separation methods [64–66]. The production and the guid-
ing principles behind the generation of prefractionated libraries
have been recently reviewed [67,68]. Prefractionated extracts
are considerably less complex than crude extracts, which enables
screening at a high concentration and simplifies dereplication.
Although enriched extracts allow the detection of minor compo-
nents during screening, it is not possible to remove all interfering
or frequent hitting compounds that will also be enriched. Pre-
fractionated extracts also facilitate the unmasking of active com-
pounds from cytotoxic compounds and agonists from antago-
nists.
The ultimate prefractionated library is a pure natural product li-
brary that has a structurally diverse set of natural products withknown structures and physicochemical properties and > 95% pu-
rity. Pure natural product libraries are assembled in an iterative
manner from in-house isolated compounds and natural products
purchased from commercial sources. The largest commercial
player in this area is AnalytiCon Discovery GmbH (Potsdam, Ger-
many; http://www.ac-discovery.com/). AnalytiCon have as-
sembled a 25000 pure natural product library over the last 20
years based on about 2000 different chemotypes that are avail-
able in a ready-for-screening format [69,70]. The only other de-
scription [71] of a pure natural product library was a plant-based
library from MolecularNature Ltd., which is now available via
PhytoQuest Ltd. (Aberystwyth, United Kingdom; http://www.
phytoquest.co.uk/). Screening of this type of library is especially
attractive for groups not interested in bioassay-guided isolation
that still want to access natural product diversity.
A few words of caution: although it may seem attractive to gen-
erate large numbers of pure natural products and prefractionated
extracts for screening, there is considerable effort and monetary
investment required to generate, store and undertake quality
control analyses [1]. There is also an increase in screening costs
for each extra screening point and, as a consequence, the optimal
number of fractions needs to be carefully considered. There also
can be a loss in biodiversity coverage when screening prefrac-
tions, especially if the screening capacity is limited. To achieve
optimal metabolite coverage in the minimum number of screen-
ing points, organism taxonomy studies along with robust assess-
ments of the extract quality and chemical diversity must be
undertaken before generating fractions [72–75].
Before assembling the library, a decision is required about
whether samples will be tested at equivalent µg/mL concentra-
tions, which requires the weighing of each extract or prefraction,
or at equivalent doses relative to a broth volume or amount of
material extracted. Both methods have their advantages and dis-
advantages.Maintaining and Storing a Natural Product Library
!
Organism storage
Dried plant material is usually stored at room temperature as a
finely ground powder tominimize storage space and enhance ex-
traction. Plant samples, especially intact plant parts, need to be
periodically inspected for microorganism growth to identify con-
tamination. Microorganism stock cultures are usually stored fro-
zen (liquid nitrogen and − 80°C freezer) [76,77] as glycerol stocks
or freeze-dried [78]. It is prudent to duplicate the microorganism
collection in two separate locations in case of a catastrophic
event that would destroy the freezer contents. It is also prudent
to keep multiple stock copies of each microorganism to give the
best chance of revival. Marine invertebrate samples can be stored
in a − 4°C freezer with or without the extraction solvent.
Extract and pure natural product storage and stability
Extracts and pure natural products are usually best stored dried
under a dry, inert atmosphere at − 20°C or below; however, these
solid materials are not easily manipulated for screening pur-
poses. One way around this problem is to aliquot the solid mate-
rial at the desired screening concentrations, remove the solvent
and store ready for screening. This dry plating method also has
its disadvantages: the screening concentration is fixed, there
could be issues with extract dissolution and some assays require
the testing material to be added after the reagents and media. AnButler MS et al. Natural Product Libraries:… Planta Med 2014; 80: 1161–1170
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.alternative method is to dissolve the extracts and compounds in
dry DMSO, which is a hygroscopic liquid that freezes at 18.5°C,
and dispense aliquots of this solution at the desired concentra-
tion. The dispensing is best performed using automated robots
but can also be performed manually on a smaller scale. It has
been shown that storing the DMSO stock solution as a solid can
cause issues with compound stability and solubility that worsens
with each freeze-thaw cycle [79–81]. A stability study of syn-
thetic compound DMSO stocks stored at room temperature
showed that a concentration of 8% of the compounds has signifi-
cantly decreased after 3 months, 17% after 6 months, and 48%
after 1 year [82]. Interestingly, a recent paper has suggested that
compound purity is themost important factor for stability of syn-
thetic compounds [81]. On face value this implies that natural
product extracts could be especially unstable but in reality the
presence of other compounds increases compound solubility
and stability inside the extracts. The presence of antioxidants al-
so helps with compound stability in extracts.
It is almost impossible for the average laboratory to totally ex-
clude H2O from DMSO solutions during the storage and dispens-
ing phases. In this situation, DMSO stocks should be dispensed
and stored for only a limited amount of time (say < 2 months)
and the number of freeze-thaw cycles kept to a minimum. An ex-
ample of a sophisticated compound and extract storage and dis-
pensing facility is the Queensland Compound Library (http://
www.griffith.edu.au/science-aviation/queensland-compound-li-
brary), which is housed at Griffith University (Brisbane, Austral-
ia). In this facility, compounds and extracts have a unique 2D bar-
code, which is used to track samples through the whole process
from the automated weighing station to the plate dispensing for
screening. The solid samples are stored in the dark under an inert
and dry atmosphere at − 20°C [83]. The screening samples are
dissolved in dry DMSO and stored in liquid form under a dry N2
atmosphere for up to 5–6 years. Individual or sets of these
screening samples are then assembled using the 2D barcode and
transferred using an acoustic dispenser [84] in any format re-
quired for screening (e.g., 96-, 384-, or 1356-well microtiter
plates). Periodic analyses of the screening samples using LC‑MS
are undertaken for quality control purposes.
Although state-of-the-art storage, dispensing, and analysis facili-
ties increase the probability of identifying bioactive molecules,
inexpensive and simple procedures like minimizing water in the
DMSO stocks, limiting freeze-thaw cycles, and not using “expired
DMSO stocks” go a long way to improving assay outcomes with-
out significant monetary outlays.D
oPracticalities of Screening Natural Product Libraries
!
A natural product extract can contain hundreds to thousands of
compounds that have a wide molecular weight, polarity, and
abundance ranges. Before bioassay-guided isolation can be used
to identify the compounds responsible for the activity, medici-
nally relevant and robust assays need to be developed, which
can be divided into in vitro biochemical and cell-based assays.
The biochemical assays are grouped into two subtypes based on
their complexity and troubleshooting difficulty: binary assays or
direct binding assays involving two partners (ligand and an ana-
lyte or binding partner) or ternary assays (ligand, analyte, and a
ligand-analyte modulator). The use of more complex, more bio-
logically relevant cell-based assays has steadily increased over
the past several years [85], and they can be further divided intoButler MS et al. Natural Product Libraries:… Planta Med 2014; 80: 1161–1170reporter, morphometric, and homogenous assays. Reporter
assays use fluorescent and/or luminescent labels to monitor
changes in protein expression or protein-protein clustering or in-
teraction, while morphometric assays involve the measurement
of changes in growth, cytotoxicity, and subcellular morphologic
features using quantitative microscopy and label-free techniques.
Finally, homogenous assays include a lysis step before readout
and could almost be considered as biochemical assays. Electro-
physiology and flow cytometry assays stand on their own as they
involve a cell sorting step and a cell-by-cell readout.
Developing representative screening sets
to interrogate screen robustness
The concept of the natural product matrix effect: An extract is a
complex genus and media specific mixture or matrix that can in-
terfere with the assay dynamic range, signal-to-noise ratio, and
reproducibility. Although a solvent-vehicle can be used as a base-
line control, an inactive extract representative of the libraryʼs
“average” matrix can also be used. It is important that the in-
active extract matrix be representative of the average matrices
of the other extracts. For example, the “generic inactive extract”
for amarine invertebrate n-BuOH extract library can be produced
by pooling whole EtOH extracts from three to five randomly se-
lected library specimens, drying the extracts and partitioning be-
tween H2O and n-BuOH. The n-BuOH layer is dried, weighed and
adjusted to the desired w/v concentration required for the stock
solution. This solution is left on the laboratory bench for one
week under ambient laboratory fluorescent light to generate the
final “generic inactive extract”.
Positive and negative controls: This “generic inactive extract” is
then used as the negative control or baseline for the screening
campaign. If an active small molecule has been previously identi-
fied, positive controls and/or standard curves should be gener-
ated using the same “generic inactive extract” spiked with the
known active compound. Simple positive controls in the solvent
should also be run in parallel to establish the “matrix effect” on
the assay dynamic range, signal to noise ratio, and reproducibil-
ity.
For some biological targets, no active molecules have been iden-
tified. For homogenous assays that use recombinantly expressed
purified proteins or membrane preparations, chaotropic agents
such as guanidine and SDS can be used as positive controls due
their denaturing effect. Care needs to be taken as these types of
positive controls can be misleading when trying to establish as-
say tolerability to the vehicle-solvent concentration, as they can
trigger the expected assay response, even at a high vehicle-sol-
vent concentration, while displaying the hallmarks of a working
assay (e.g., stable baseline, no precipitation, and a large dynamic
range). However, the assay may no longer be able to detect an ac-
tive compound using these conditions. Residual solvent in the
samples such as n-BuOH can also act itself as a chaotropic agent,
disrupting the structure of, or worse, denaturing proteins [86]. A
rule-of-thumb is to assume that there is no tolerance to the sol-
vent in these assays until an active compound has been identified
suitable for use as a positive control.
The solvent effect can be avoided if the vehicle-solvent used to
transfer a library in the assay microtiter plate can be evaporated
and the extract resuspended in assay buffer. Inmost cases, the re-
suspension of extracts/prefractions is straightforward except for
a small number of extracts that can emulsify during the brisk ag-
itation in the assay buffer. The effect of this transfer, drying, and
Fig. 2 Screening at high concentrations (Zone 1) leads to higher hit rates
(continuous line) that identify a predominance of compounds with low
target affinity (dashed line). For example, screening a set of marine inver-
tebrate extracts at 10 µg/mL w/v with compounds at a relative abundance
of 1–10% (average MW of 500) is equivalent to testing pure compounds in
the 0.2 to 2 µM range, which often results in the identification of hits in the
mid- to low µM affinity range. Although mid- to low nM actives can also be
identified when screening in Zone 1, the extract matrix effect and com-
pound interference can also mask the activity. Screening in Zone 1 for cell-
based assays where cytotoxicity often leads to “bell-shaped” dose-response
curves will miss relatively abundant mid- to low nM actives. Screening the
extracts at 10- and 100-fold lower concentrations (Zone 2 and Zone 3) re-
duces the matrix and interference effects leading to identification of ex-
tracts that would have be missed or not prioritized when screening in Zone
1. As a consequence, we recommend screening natural product extracts
and prefractions when practicable using at least two concentrations, espe-
cially for cell-based screening.
1165Review
D
ow
nl
oa
de
d 
by
: I
P-
Pr
ox
y 
Un
ive
rs
ity
_Q
ue
en
sla
nd
, U
niv
er
sit
y o
f Q
ue
en
sla
nd
. C
op
yr
igh
te
d 
m
at
er
ial
.resuspension cycle should also be evaluated on the positive con-
trol (generic inactive extract spiked with active compound).
Assay optimization and pilot study: The experimental conditions
of each assay need to be optimized in regards to parameters such
as reagent and extract concentrations, reagent addition times,
endpoint window to account for different instrument reading
times, replicate reproducibility, and DMSO tolerance. Once these
parameters have been established, a pilot study is undertaken on
a subset of representative extracts and prefractions, and the pure
natural product library. The data from the representative extracts
is then analyzed for assay robustness and from these results,
promising hits are moved to the dereplication stage. These data
can also be extrapolated to give an estimated overall assay hit
rate. The pure natural product library is used to identify com-
pounds of interest and frequent hitters that are flagged for dere-
plication.
For an example of this process, consider the marine invertebrate
n-BuOH extract library, which has already been formatted in a
screening-ready format in deep 96-well plates. The extracts were
formatted at several w/v concentrations (25, 2.5, and 0.25mg/
mL), relative to the initial concentration of the whole extract be-
fore n-BuOH/H2O partition. These concentrations offer flexibility
and accuracy when plating sub-mg tomg amounts in assay wells,
where incubation volumes range from 10 to 250 µL.
Cytotoxicity is not an issue for cell-based assay protocols that use
short incubation times (30–45 minutes) or homogenous assays,
and extracts in the several hundreds of µg/mL can be used in
these assays. For cell-based assays that require longer incubation
times, usually only concentrations less than 10 µg/mL can be used
to avoid observing toxicity. Cell toxicity should be tested with a
large concentration range of “generic inactive extract”, e.g., 0 to
500 µg/mL, using alamarBlue, cytosolic lactose dehydrogenase
release, or similar readouts, in order to estimate the EC50 profile
of the library genus matrix. The incubation duration depends on
the assay type and can vary from 30 minutes for ion channel cell-
based assays [87,88] to 15–18 hours for a lipid droplet formation
assay [89,90], or up to four days for a stem cell commitment assay
that was developed to identify molecules stimulating commit-
ment of neural precursor cells to neuronal lineage [91,92]. Care
needs to be takenwhen using DMSO-containing libraries as most
cell-based assays can only tolerate < 0.5% DMSO.
The next step is to decide whether the natural product library
will be screened at a single concentration or at multiple concen-
trations in singlicate or duplicate experiments. The two extremes
are libraries screened at a single concentration in singlicate and
libraries screened using quantitative HTS (qHTS), in which sam-
ples are screened at multiple concentrations to generate concen-
tration-response curves [93,94]. The limited supply of some nat-
ural product extracts is also a consideration when deciding on
screening numbers. Wewould recommend screening at two con-
centrations when practicable, usually 10- to 100-fold apart
(l" Fig. 2). Besides providing concentration-dependence informa-
tion, these data are useful for ranking hits in order of potency, as
well as identifying extracts that are only active at the lower con-
centration. Extracts not active at the higher concentration could
have their activitymasked by amatrix effect or cell cytotoxicity or
be false positives. Examples of screenings of a natural product li-
brary at low to very low concentrations are starting to appear in
the literature [95]. We recommend that this strategy be used for
cell-based assays, but it can also be used for biochemical assays.Matrix components that lead to assay interference
Colored or fluorescent compounds: These types of compounds can
interfere with colorimetric and fluorescent assays and result in
both false positives and negatives depending upon the assay
readout. For example, compounds with molecular weights in
the range of 300 to 600 Da can be yellow to red in color, which
can interfere with the colorimetric readouts, or absorb and fluo-
resce in a yellow-green spectrum range similar to fluorescein,
which is commonly used in fluorescence polarization-based
binding competition assays [96]. As these compounds are often
present in the assay in the µM range, which is around 1000-fold
higher than the assay probe present in the nM range, most of the
energy of excitation will be absorbed by the compounds and
probe-derived fluorescence will decrease accordingly. In fluores-
cence polarization-based assays, fluorescence interference will
decrease the total fluorescence (parallel and perpendicular) and
increase the calculated fluorescent polarization ratios. Fluores-
cence interference in these types of assays can be decreased by
using far-red fluorescent probes [96].Butler MS et al. Natural Product Libraries:… Planta Med 2014; 80: 1161–1170
Fig. 3 Schematic of a typical dereplication process. Up to 1mg of crude
extract or prefraction are separated using HPLC (C18 column) and the eluting
compounds analyzed using a photodiode array detector (PDA). The eluent is
then split with a majority flowing into a microtiter plate and the remainder
analyzed using ESI‑MS and MS/MS. The microtiter plate contents are dried
using centrifugal evaporation and DMSO is added to each well ready for
screening. It is prudent to add the crude extract or originating fraction to the
plate at two concentrations for comparative purposes. The (A) retention time
(RT), (B) UV spectra, (C) MS, and (D) MS/MS of compounds present in the
active fractions are analyzed and compared to in-house databases and com-
mercial software such as the Dictionary of Natural Products (Taylor & Francis
Group), MarinLit (Royal Society of Chemistry), AntiBase (Wiley-VCH), and
SciFinder (American Chemical Society). Work is discontinued on samples
where the activity is accounted by the identified compound or compounds,
while like extracts are grouped for further evaluation.
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.Micelle formation and aggregation: Some extracts, prefractions,
and pure compounds can form micelles in assay buffer that can
destabilize a purified system (recombinant protein, membrane
preparation) in a biochemical assay. The micelles can cause toxic-
ity in cell-based assays, while in homogeneous assays they can
trap fluorescent probes, fluorescent chemosensors, or fluores-
cence-tagged reagents leading to a high local concentration that
can interfere with the fluorescence readout (quenching) or pre-
vent functional chemosensing. Micelles are usually formed by de-
tergent-like molecules such as fatty acids and sulfated com-
pounds, but this behavior can also be observed with other types
of molecules. Simple assays are available to measure critical mi-
celle concentration (CMC) and can easily be implemented in 96-
or 384-well plate format [97]. Detergent-like molecules present
can also form colloidal aggregations that cause assay interference
[98–102], which can usually be identified through the addition of
detergent to disrupt aggregation [98,103]. Finally, there have also
been reports of detergent-like molecules being released from the
plasticware that can cause assay interference [104,105].
Media-derived interference: The media used to growmicroorgan-
isms is often a soup of diverse ingredients that include salts, ami-
no acids, proteins, and complex biological products. Some assays
are sensitive to the different salts [106] such as FLIPR assays that
detect Ca2+ flux [107], or assays involving metalloproteases,
which contain cations in their active sites [108]. Other examples
include the production of large amounts of aluminum dioxalate
by some fungi grown using vermiculite-based solid media [109]
and the bacterial biotransformation of soybean-derived glycosy-
lated isoflavones to the biologically active aglycones genistein
and daidzein.
Pan-active bioactive compounds: Broad-spectrum kinase and
protease are pivotal modulators of cell protein-protein interac-
tions and cell signaling. The abundance of these broad-spectrum
cell-signaling modulators in some natural extracts may “para-
lyze” cells, without the usual hallmarks of cytotoxicity, and mask
compounds of biological interest, which need a “functional cell”
to modulate a phenotype, like cell differentiation, secretion, and
trafficking. Examples include bacteria and marine invertebrate
extracts that contain staurosporine-like kinase inhibitors [110],
and marine algae and venom extracts that contain protease in-
hibitors [111,112].Butler MS et al. Natural Product Libraries:… Planta Med 2014; 80: 1161–1170Moving from the assay to bioactive compounds
Assay quality control: Z-factor (or Z′ analyses) is a statistical
method used to indicate whether an assay is suitable for HTS
campaigns [113]. Z-factor is an important quality control that
should be calculated for every completed assay microtiter plate.
The value should remain relatively constant during screening,
but if a variation is observed, then there could be issues with the
screen performance. These variations can be caused by poor li-
brary quality, batch-to-batch cell and protein quality differences,
incorrect assay optimization, or instrument issues. The Z-factor
can vary from poor (Z < 0), which can occur if there is too much
overlap between negative and positive controls, marginal (0 <
Z < 0.5), and excellent (0.5 < Z < 1) assay quality. In many instan-
ces, assays cannot be optimized beyond the marginal level, but
this is often sufficient for screening with extra care taken to ana-
lyze the data. For example, for fluorescence polarization assays,
the signal-to-noise ratio is usually in the 1.5 to 4 range leading
to Z-factors of around 0.5, but this assay format is precise, robust,
and reproducible and, in our opinion, the technology of choice for
homogeneous-type assays to screen natural products [114].
The hit rate determined during the pilot study of the various li-
brary subclasses can also be extrapolated to the larger screening
sets. If the hit rates diverge considerably between the pilot study
and the screening campaign, then it is worth further analysis of
the hits as this could be a flag for poor assay performance and ex-
tract quality.
Prioritizing extracts/prefractions for evaluation and bioassay-
guided isolation: During the screening campaign, it is recom-
mended that carefully selected assay hits from the different
screening libraries enter the dereplication [68,70,115,116] stage
to identify commonly occurring active compounds and to get a
head start on identifying new bioactive molecules (l" Fig. 3).
Once the screening campaign is completed, then the overall hit
rate of the screen can be calculated. The hit rate is usually be-
tween 0% to 5% depending upon the assay setup and hit selection
cutoff, but for some screens such as cell line cytotoxicity and
gram-positive bacteria whole cell assays, the hit rate can be up
to 15% depending upon the library.
First, letʼs consider a manageable hit rate of around 0.2 to 0.5%,
which would involve further evaluation of 200 to 500 samples
from screening of a 100000 member library. The active samples
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.are first cherry-picked from the library and then retested in the
screening assay to confirm activity. The next stage is to obtain a
4-log fold range dose response on the retested positive samples
and then test in appropriate orthogonal and secondary assays.
An orthogonal assay is the same target as the HTS assay but in a
different screening format that is used to help identify false pos-
itive results. Orthogonal assays are especially important when
screening crude extracts due to the potential for a variety of in-
terference compounds. Frequently run secondary assays include
whole cell cytotoxicity, antifungal, gram-positive and gram-neg-
ative bacteria screening, and protease, kinase, and GPCR panel
profiling to analyze for specificity. The retesting and secondary
screening phases usually take at least 2 weeks depending upon
the amount of secondary screening required. The number of
samples for further evaluation should now have been reduced to
below 50 and after dereplication will result in a reasonable num-
ber for bioassay-guided isolation.
However, what do you do with a hit rate of around 5 to 10%,
which would involve further evaluation of 5000 to 10000 sam-
ples from screening a 100000 member library? An example of a
screen with a potentially high hit rate is the screening of bacteri-
al-derived extracts and prefractions against the gram-positive
bacteria Staphylococcus aureus. The hit rate could be lowered by
raising the cutoff threshold, but this is risky as extracts or pre-
fractions that contain lower abundance actives will not be se-
lected and potential leads not identified. The only practical way
forward with this number of extracts is to undertake considera-
ble secondary screening or cross-referencing with existing
screening data, as well as undertaking considerable dereplica-
tion, either through sheer force of numbers or by rapid analysis
for common hitting compounds by LC‑MS/MS without sample
collection. Extracts can be further clustered by their biological
profiles, dereplication profiles, and taxonomy.
The next step is to undertake bioassay-guided isolation [24,117,
118] to identify the bioactive compounds present in the extract.
Guided by the dereplication profile, a chromatography step is
undertaken, and the fractions are subjected to testing alongside
the crude extract or originating fraction. This process is repeated
until themost active compound or compounds are identified that
account for the activity of the extract or prefraction. For biologi-
cal evaluation, the compound needs to have > 95% purity, espe-
cially for structure-activity studies. Always be on the lookout for
samples where there could be a minor component present that is
significantly adding to, or responsible for, the activity. For exam-
ple, for µM active compounds, the presence < 1% of an nM active
compound could account for the activity and not be able to be
identified by NMR or even LC‑MS. If this is a possibility, then iso-
late related compounds to see if they are active or collect sub-
fractions of the peak and look for fractions that are equally active.Conclusion
!
The unique chemical structures and biological activities of natu-
ral products make them attractive candidates for drug lead dis-
covery and as chemical probes. Most large pharmaceutical com-
panies have abandoned natural product-based lead discovery,
which has created great opportunities for university-based re-
search groups and small biotechnology companies. Expertise is
often available in these organizations to validate the drug leads
and undertake preclinical drug development using in-house re-
sources and CROs. However, if natural product-based librariesare going to be efficiently used to screen for new drug leads, they
need to be of the highest quality. To start assembling this type of
library, we first recommend that analysis methods (including
dereplication) to assess metabolite diversity are implemented,
all organisms used to generate the library are taxonomically
identified, and a pure natural product library is assembled to aid
in pilot screening studies and dereplication. The library should be
a balancedmixture of crude extracts, prefractions, and pure com-
pounds to optimize taxonomic and chemical space coverage,
while minimizing the number of screening points. The library
should be subdivided into smaller screening sets based on taxon-
omy, microorganism cultivation conditions, and sample prepara-
tion methods. The library should also be dynamic with extracts
and prefractions added and removed from the library in response
to chemical analyses and screening results. The next step in the
process is to develop (or work out with collaborators) robust as-
says that are suitable for screening natural product samples. Or-
thogonal assays also need to be developed to help identify false
positive results, as well as secondary assays to help select the best
hits for further evaluation. Before full scale campaign screening is
undertaken, a pilot study needs to be completed and the data an-
alyzed. We also recommend that the library is screened at two
concentrations when practicable, especially for cell-based assays.
Active samples are dereplicated, and selected samples then
undergo bioassay-guided isolation to identify the active com-
pound(s) responsible for the activity. With luck, these biologi-
cally active compounds have the potential to be new drug leads
and chemical probes.Acknowledgements
!
This paper was prepared with the support of NHMRC grant
AF511105. MSB is supported by a Wellcome Trust Seeding Drug
Discovery Award (094977/Z/10/Z).Conflict of Interest
!
The authors declare no competing financial interest.
References
1 Butler MS. The role of natural product chemistry in drug discovery.
J Nat Prod 2004; 67: 2141–2153
2 Butler MS. Natural products to drugs: natural product-derived com-
pounds in clinical trials. Nat Prod Rep 2008; 25: 475–516
3 Cragg GM, Newman DJ. Natural products: a continuing source of novel
drug leads. Biochim Biophys Acta 2013; 1830: 3670–3695
4 Newman DJ, Cragg GM. Natural products as sources of new drugs over
the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311–335
5 Hopkins AL, Bickerton GR. Drug discovery: Know your chemical space.
Nat Chem Biol 2010; 6: 482–483
6 Henkel T, Brunne RM, Müller H, Reichel F. Statistical investigation into
the structural complementarity of natural products and synthetic
compounds. Angew Chem Int Ed 1999; 38: 643–647
7 Singh SB, Culberson JC. Chemical space and the difference between nat-
ural products and synthetics. In: Buss AD, Butler MS, editors. Natural
product chemistry for drug discovery. Cambridge: Royal Society of
Chemistry; 2010: 28–43
8 Lachance H, Wetzel S, Kumar K, Waldmann H. Charting, navigating, and
populating natural product chemical space for drug discovery. J Med
Chem 2012; 55: 5989–6001
9 Vasilevich NI, Kombarov RV, Genis DV, Kirpichenok MA. Lessons from
natural products chemistry can offer novel approaches for synthetic
chemistry in drug discovery. J Med Chem 2012; 55: 7003–7009Butler MS et al. Natural Product Libraries:… Planta Med 2014; 80: 1161–1170
1168 Review
D
ow
nl
oa
de
d 
by
: I
P-
Pr
ox
y 
Un
ive
rs
ity
_Q
ue
en
sla
nd
, U
niv
er
sit
y o
f Q
ue
en
sla
nd
. C
op
yr
igh
te
d 
m
at
er
ial
.10 Koehn FE. High impact technologies for natural products screening.
Prog Drug Res 2008; 65: 175, 177–210
11 Koehn FE, Carter GT. The evolving role of natural products in drug dis-
covery. Nat Rev Drug Discov 2005; 4: 206–220
12 Yu MJ, ZhengW, Seletsky BM. Frommicrograms to grams: scale-up syn-
thesis of eribulin mesylate. Nat Prod Rep 2013; 30: 1158–1164
13 Jackson KL, Henderson JA, Phillips AJ. The halichondrins and E7389.
Chem Rev 2009; 109: 3044–3079
14 Cuevas C, Pérez M, Martín MJ, Chicharro JL, Fernández-Rivas C, Flores M,
Francesch A, Gallego P, Zarzuelo M, de la Calle F, García J, Polanco C,
Rodríguez I, Manzanares I. Synthesis of ecteinascidin ET‑743 and
phthalascidin Pt-650 from cyanosafracin B. Org Lett 2000; 2: 2545–
2548
15 Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from
marine natural products. Nat Rev Drug Discov 2009; 8: 69–85
16 Kantarjian HM, OʼBrien S, Cortes J. Homoharringtonine/omacetaxine
mepesuccinate: the long and winding road to food and drug adminis-
tration approval. Clin Lymphoma Myeloma Leuk 2013; 13: 530–533
17 Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and com-
putational approaches to estimate solubility and permeability in drug
discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3–
26
18 Ganesan A. The impact of natural products upon modern drug discov-
ery. Curr Opin Chem Biol 2008; 12: 306–317
19 Pereira DA, Williams JA. Origin and evolution of high throughput
screening. Br J Pharmacol 2007; 152: 53–61
20 Maréchal E, Roy S, Lafanechère L. The pharmacological screening pro-
cess: the small molecule, the biological screen, the robot, the signal
and the information. In: Maréchal E, Roy S, Lafanechère L, editors. Che-
mogenomics and chemical genetics: a userʼs introduction for biolo-
gists, chemists and informaticians. Berlin: Springer-Verlag; 2011: 7–21
21 Knibiehler M. Theminiaturised biological assay: constraints and limita-
tions. In: Maréchal E, Roy S, Lafanechère L, editors. Chemogenomics
and chemical genetics: a userʼs introduction for biologists, chemists
and informaticians. Berlin: Springer-Verlag; 2011: 29–42
22 Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T,
Green DVS, Hertzberg RP, Janzen WP, Paslay JW, Schopfer U, Sittampalam
GS. Impact of high-throughput screening in biomedical research. Nat
Rev Drug Discov 2011; 10: 188–195
23 Lane RF, Friedman LG, Keith C, Braithwaite SP, Frearson JA, Lowe DA, Lon-
go FM, Refolo LM, Watterson DM, Tsaioun K, Shineman DW, Fillit HM.
Optimizing the use of CROs by academia and small companies. Nat
Rev Drug Discov 2013; 12: 487–488
24 Bucar F, Wube A, Schmid M.Natural product isolation – how to get from
biological material to pure compounds. Nat Prod Rep 2013; 30: 525–
545
25 Seidel V. Initial and bulk extraction of natural products isolation. In:
Sarker SD, Nahar L, editors. Natural products isolation. Totowa: Hu-
mana Press; 2012: 27–41
26 Esclapez MD, García-Pérez JV, Mulet A, Cárcel JA. Ultrasound-assisted
extraction of natural products. Food Eng Rev 2011; 3: 108–120
27 Mason TJ, Chemat F, Vinatoru M. The extraction of natural products us-
ing ultrasound or microwaves. Curr Org Chem 2011; 15: 237–247
28 Chan CH, Yusoff R, Ngoh GC, Kung FWL.Microwave-assisted extractions
of active ingredients from plants. J Chromatogr A 2011; 1218: 6213–
6225
29 Richter BE, Jones BA, Ezzell JL, Porter NL, Avdalovic N, Pohl C. Accelerated
solvent extraction: A technique for sample preparation. Anal Chem
1996; 68: 1033–1039
30 Herrero M, Mendiola JA, Cifuentes A, Ibáñez E. Supercritical fluid extrac-
tion: Recent advances and applications. J Chromatogr A 2010; 1217:
2495–2511
31 Fornari T, Vicente G, Vázquez E, García-Risco MR, Reglero G. Isolation of
essential oil from different plants and herbs by supercritical fluid ex-
traction. J Chromatogr A 2012; 1250: 34–48
32 Tang B, Bi W, Tian M, Row KH. Application of ionic liquid for extraction
and separation of bioactive compounds from plants. J Chromatogr B
2012; 904: 1–21
33 Dai Y, van Spronsen J, Witkamp GJ, Verpoorte R, Choi YH. Natural deep
eutectic solvents as new potential media for green technology. Anal
Chim Acta 2013; 766: 61–68
34 Dai Y, Witkamp GJ, Verpoorte R, Choi YH. Natural deep eutectic solvents
as a new extraction media for phenolic metabolites in Carthamus tinc-
torius L. Anal Chem 2013; 85: 6272–6278Butler MS et al. Natural Product Libraries:… Planta Med 2014; 80: 1161–117035 Corson TW, Crews CM. Molecular understanding and modern applica-
tion of traditional medicines: triumphs and trials. Cell 2007; 130:
769–774
36 Ngo LT, Okogun JI, Folk WR. 21st Century natural product research and
drug development and traditional medicines. Nat Prod Rep 2013; 30:
584–592
37 Jones W, Kinghorn AD. Extraction of plant secondary metabolites. In:
Sarker SD, Nahar L, editors. Natural products isolation. Totowa: Hu-
mana Press; 2012: 341–366
38 Tan GT, Pezzuto JM, Kinghorn AD, Hughes SH. Evaluation of natural
products as inhibitors of human immunodeficiency virus type 1
(HIV‑1) reverse transcriptase. J Nat Prod 1991; 54: 143–154
39 Collins RA, Ng TB, Fong WP, Wan CC, Yeung HW. Removal of poly-
phenolic compounds from aqueous plant extracts using polyamide
minicolumns. IUBMB Life 1998; 45: 791–796
40 Cordell GA, Quinn-Beattie ML, Farnsworth NR. The potential of alkaloids
in drug discovery. Phytother Res 2001; 15: 183–205
41 Butler MS, Katavic PL, Davis RA, Forster PI, Guymer GP, Quinn RJ. 10-Hy-
droxydarlingine, a new tropane alkaloid from the Australian protea-
ceous plant Triunia erythrocarpa. J Nat Prod 2000; 63: 688–689
42 Duetz WA. Microtiter plates as mini-bioreactors: miniaturization of
fermentation methods. Trends Microbiol 2007; 15: 469–475
43 Siebenberg S, Bapat PM, Lantz AE, Gust B, Heide L. Reducing the variabil-
ity of antibiotic production in Streptomyces by cultivation in 24-square
deepwell plates. J Biosci Bioeng 2010; 109: 230–234
44 Berrue F, Withers ST, Haltli B, Withers J, Kerr RG. Chemical screening
method for the rapid identification of microbial sources of marine in-
vertebrate-associated metabolites. Mar Drugs 2011; 9: 369–381
45 Phillips T, Chase M, Wagner S, Renzi C, Powell M, DeAngelo J, Michels P.
Use of in situ solid-phase adsorption in microbial natural product fer-
mentation development. J Indian Microbiol Biotechnol 2013; 40: 411–
425
46 Adelin E, Martin MT, Cortial S, Retailleau P, Lumyong S, Ouazzani J. Bio-
active polyketides isolated from agar-supported fermentation of Pho-
mopsis sp. CMU‑LMA, taking advantage of the scale-up device, Plato-
tex. Phytochemistry 2013; 93: 170–175
47 Goff G, Adelin E, Cortial S, Servy C, Ouazzani J. Application of solid-phase
extraction to agar-supported fermentation. Bioprocess Biosyst Eng
2013; 36: 1285–1290
48 Bode HB, Bethe B, Höfs R, Zeeck A. Big effects from small changes: possi-
ble ways to explore natureʼs chemical diversity. Chem Biochem 2002;
3: 619–627
49 Cichewicz RH. Epigenome manipulation as a pathway to new natural
product scaffolds and their congeners. Nat Prod Rep 2010; 27: 11–22
50 Lim FY, Sanchez JF, Wang CCC, Keller NP. Toward awakening cryptic sec-
ondarymetabolite gene clusters in filamentous fungi. In: David AH, ed-
itor. Methods enzymol. Waltham: Academic Press; 2012: 303–324
51 Pettit RK. Small-molecule elicitation of microbial secondary metabo-
lites. Microb Biotechnol 2011; 4: 471–478
52 Scherlach K, Hertweck C. Triggering cryptic natural product biosynthe-
sis in microorganisms. Org Biomol Chem 2009; 7: 1753–1760
53 Ochi K, Hosaka T. New strategies for drug discovery: activation of silent
or weakly expressed microbial gene clusters. Appl Microbiol Biotech-
nol 2013; 97: 87–98
54 JohnsonTA, MorganMVC, Aratow NA, Estee SA, Sashidhara KV, Loveridge
ST, Segraves NL, Crews P. Assessing pressurized liquid extraction for the
high-throughput extraction of marine-sponge-derived natural prod-
ucts. J Nat Prod 2009; 73: 359–364
55 Eldridge GR, Vervoort HC, Lee CM, Cremin PA, Williams CT, Hart SM,
Goering MG, OʼNeil-Johnson M, Zeng L. High-throughput method for
the production and analysis of large natural product libraries for drug
discovery. Anal Chem 2002; 74: 3963–3971
56 Jia Q. Generating and screening a natural product library for cyclooxy-
genase and lipoxygenase dual inhibitors. In: Atta ur Rahman, editor.
Studies in natural products chemistry. Amsterdam: Elsevier; 2003:
643–718
57 Appleton DR, Buss AD, Butler MS. A simple method for high-throughput
extract prefractionation for biological screening. Chimia 2007; 61:
327–331
58 WagenaarMM. Pre-fractionatedmicrobial samples – the second gener-
ation natural products library at Wyeth. Molecules 2008; 13: 1406–
1426
59 Bugni TS, Harper MK, McCulloch MWB, Reppart J, Ireland CM. Fraction-
ated marine invertebrate extract libraries for drug discovery. Mole-
cules 2008; 13: 1372–1383
1169Review
D
ow
nl
oa
de
d 
by
: I
P-
Pr
ox
y 
Un
ive
rs
ity
_Q
ue
en
sla
nd
, U
niv
er
sit
y o
f Q
ue
en
sla
nd
. C
op
yr
igh
te
d 
m
at
er
ial
.60 Quinn RJ, Carroll AR, Pham NB, Baron P, PalframanME, Suraweera L, Pie-
rens GK, Muresan S. Developing a drug-like natural product library.
J Nat Prod 2008; 71: 464–468
61 Tu Y, Jeffries C, Ruan H, Nelson C, Smithson D, Shelat AA, Brown KM, Li XC,
Hester JP, Smillie T, Khan IA, Walker L, Guy K, Yan B. Automated high-
throughput system to fractionate plant natural products for drug dis-
covery. J Nat Prod 2010; 73: 751–754
62 Camp D, Davis RA, Campitelli M, Ebdon J, Quinn RJ. Drug-like properties:
guiding principles for the design of natural product libraries. J Nat Prod
2011; 75: 72–81
63 Camp D, Campitelli M, Carroll AR, Davis RA, Quinn RJ. Front-loading nat-
ural-product-screening libraries for log P: background, development,
and implementation. Chem Biodivers 2013; 10: 524–537
64 Alvi KA, Peterson J, Hofmann B. Rapid identification of elaiophylin and
geldanamycin in Streptomyces fermentation broths using CPC coupled
with a photodiode array detector and LC‑MS methodologies. J Indian
Microbiol 1995; 15: 80–84
65 Armbruster JA, Borris RP, Jimenez Q, Zamora N, Tamayo-Castillo G, Har-
ris GH. Separation of crude plant extracts with high speed CCC for pri-
mary screening in drug discovery. J Liq Chromatogr Relat Technol
2001; 24: 1827–1840
66 Ingkaninan K, Hazekamp A, Hoek AC, Balconi S, Verpoorte R. Application
of centrifugal partition chromatography in a general separation and
dereplication procedure for plant extracts. J Liq Chromatogr Relat
Technol 2000; 23: 2195–2208
67 Camp D, Davis RA, Evans-Illidge EA, Quinn RJ.Guiding principles for nat-
ural product drug discovery. Fut Med Chem 2012; 4: 1067–1084
68 Bugni TS, Harper MK, McCulloch MWB, Whitson EL. Chapter 9: Advances
in instrumentation, automation, dereplication and prefractionation.
In: Buss AD, Butler MS, editors. Natural product chemistry for drug dis-
covery. London: The Royal Society of Chemistry; 2009: 272–298
69 Bindseil KU, Jakupovic J, Wolf D, Lavayre J, Leboul J, van der Pyl D. Pure
compound libraries; a new perspective for natural product based drug
discovery. Drug Discov Today 2001; 6: 840–847
70 Wolf D, Siems K. Burning the hay to find the needle – data mining strat-
egies in natural product dereplication. Chimia 2007; 61: 339–345
71 Stewart M, Nash RJ, Chicarelli-Robinson MI. Production of a diverse li-
brary of plant natural products for bioassays. In: Oleszek W, Marston
A, editors. Saponins in food, feedstuffs and medicinal plants. Boston:
Kluwer Academic Publishers; 2000: 73–77
72 Kameník Z, Hadacek F, Marečková M, Ulanova D, Kopecký J, Chobot V,
Plháčková K, Olšovská J. Ultra-high-performance liquid chromatogra-
phy fingerprinting method for chemical screening of metabolites in
cultivation broth. J Chromatogr A 2010; 1217: 8016–8025
73 Hou Y, Braun DR, Michel CR, Klassen JL, Adnani N, Wyche TP, Bugni TS.
Microbial strain prioritization usingmetabolomics tools for the discov-
ery of natural products. Anal Chem 2012; 84: 4277–4283
74 Ito T, Odake T, Katoh H, Yamaguchi Y, Aoki M.High-throughput profiling
of microbial extracts. J Nat Prod 2011; 74: 983–988
75 Hsu CC, ElNaggar MS, Peng Y, Fang J, Sanchez LM, Mascuch SJ, Møller KA,
Alazzeh EK, Pikula J, Quinn RA, Zeng Y, Wolfe BE, Dutton RJ, Gerwick L,
Zhang L, Liu X, Månsson M, Dorrestein PC. Real-time metabolomics on
living microorganisms using ambient electrospray ionization flow-
probe. Anal Chem 2013; 85: 7014–7018
76 Smith D, Ryan M. Implementing best practices and validation of cryo-
preservation techniques for microorganisms. Scientific World J 2012;
2012: 805659
77 De Paoli P. Bio-banking in microbiology: from sample collection to epi-
demiology, diagnosis and research. FEMS Microbiol Rev 2005; 29:
897–910
78 Morgan CA, Herman N, White PA, Vesey G. Preservation of micro-organ-
isms by drying; a review. J Microbiol Methods 2006; 66: 183–193
79 Cheng X, Hochlowski J, Tang H, Hepp D, Beckner C, Kantor S, Schmitt R.
Studies on repository compound stability in DMSO under various con-
ditions. J Biomol Screen 2003; 8: 292–304
80 Kozikowski BA, Burt TM, Tirey DA, Williams LE, Kuzmak BR, Stanton DT,
Morand KL, Nelson SL. The effect of freeze/thaw cycles on the stability of
compounds in DMSO. J Biomol Screen 2003; 8: 210–215
81 Popa-Burke I, Novick S, Lane CA, Hogan R, Torres-Saavedra P, Hardy B,
Ray B, LindsayM, Paulus I, Miller L. The effect of initial purity on the sta-
bility of solutions in storage. J Biomol Screen 2013 Jun 19 [Epub ahead
of print] DOI: 10.1177/1087057113492201
82 Kozikowski BA, Burt TM, Tirey DA, Williams LE, Kuzmak BR, Stanton DT,
Morand KL, Nelson SL. The effect of room-temperature storage on the
stability of compounds in DMSO. J Biomol Screen 2003; 8: 205–20983 Camp D. Establishment of an open access compound management fa-
cility in Australia to stimulate applied, basic and translational bio-
medical research. Drug Discov World 2007; 2007: 61–66
84 Grant RJ, Roberts K, Pointon C, Hodgson C, Womersley L, Jones DC, Tang
E. Achieving accurate compound concentration in cell-based screen-
ing: validation of acoustic droplet ejection technology. J Biomol
Screen 2009; 14: 452–459
85 Parker CN, Ottl J, Gabriel D, Zhang JH. Advances in biological screening
for lead discovery. In: Buss AD, Butler MS, editors. Natural product
chemistry for drug discovery. London: The Royal Society of Chemis-
try; 2009: 243–271
86 Bhaganna P, Volkers RJ, Bell AN, Kluge K, Timson DJ, McGrath JW, Ruijs-
senaars HJ, Hallsworth JE. Hydrophobic substances induce water
stress in microbial cells. Microb Biotechnol 2010; 3: 701–716
87 Balansa W, Islam R, Fontaine F, Piggott AM, Zhang H, Xiao X, Webb TI,
Gilbert DF, Lynch JW, Capon RJ. Sesterterpene glycinyl-lactams: a new
class of glycine receptor modulator from Australian marine sponges
of the genus Psammocinia. Org Biomol Chem 2013; 11: 4695–4701
88 Balansa W, Islam R, Gilbert DF, Fontaine F, Xiao X, Zhang H, Piggott AM,
Lynch JW, Capon RJ. Australian marine sponge alkaloids as a new class
of glycine-gated chloride channel receptor modulator. Bioorg Med
Chem 2013; 21: 4420–4425
89 Rae J, Fontaine F, Salim AA, Lo HP, Capon RJ, Parton RG, Martin S. High-
throughput screening of Australian marine organism extracts for bio-
active molecules affecting the cellular storage of neutral lipids. PLoS
One 2011; 6: e22868
90 Salim AA, Rae J, Fontaine F, Conte MM, Khalil Z, Martin S, Parton RG,
Capon RJ. Heterofibrins: inhibitors of lipid droplet formation from a
deep-water southern Australian marine sponge, Spongia (Heterofi-
bria) sp. Org Biomol Chem 2010; 8: 3188–3194
91 Yasuda T, Adams DJ. Physiological roles of ion channels in adult neural
stem cells and their progeny. J Neurochem 2010; 114: 946–959
92 Azari H, Osborne GW, Yasuda T, Golmohammadi MG, Rahman M, De-
leyrolle LP, Esfandiari E, Adams DJ, Scheffler B, Steindler DA, Reynolds
BA. Purification of immature neuronal cells from neural stem cell
progeny. PLoS One 2011; 6: e20941
93 Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, ZhengW,
Austin CP. Quantitative high-throughput screening: A titration-based
approach that efficiently identifies biological activities in large chem-
ical libraries. Proc Natl Acad Sci U S A 2006; 103: 11473–11478
94 Cruz PG, Auld DS, Schultz PJ, Lovell S, Battaile KP, MacArthur R, Shen M,
Tamayo-Castillo G, Inglese J, Sherman DH. Titration-based screening
for evaluation of natural product extracts: identification of an aspul-
vinone family of luciferase inhibitors. Chem Biol 2011; 18: 1442–
1452
95 Cho KJ, Park JH, Piggott AM, Salim AA, Gorfe AA, Parton RG, Capon RJ,
Lacey E, Hancock JF. Staurosporines disrupt phosphatidylserine traf-
ficking and mislocalize Ras proteins. J Biol Chem 2012; 287: 43573–
43584
96 Vedvik KL, Eliason HC, Hoffman RL, Gibson JR, Kupcho KR, Somberg RL,
Vogel KW. Overcoming compound interference in fluorescence polar-
ization-based kinase assays using far-red tracers. Assay Drug Dev
Technol 2004; 2: 193–203
97 Chattopadhyay A, London E. Fluorimetric determination of critical mi-
celle concentration avoiding interference from detergent charge. Anal
Biochem 1984; 139: 408–412
98 Shoichet BK. Screening in a spirit haunted world. Drug Discov Today
2006; 11: 607–615
99 Thorne N, Auld DS, Inglese J. Apparent activity in high-throughput
screening: origins of compound-dependent assay interference. Curr
Opin Chem Biol 2010; 14: 315–324
100 Coan KED, Maltby DA, Burlingame AL, Shoichet BK. Promiscuous aggre-
gate-based inhibitors promote enzyme unfolding. J Med Chem 2009;
52: 2067–2075
101 Coan KE, Ottl J, Klumpp M. Non-stoichiometric inhibition in biochem-
ical high-throughput screening. Expert Opin Drug Discov 2011; 6:
405–417
102 Sassano MF, Doak AK, Roth BL, Shoichet BK. Colloidal aggregation
causes inhibition of G protein-coupled receptors. J Med Chem 2013;
56: 2406–2414
103 Liu Y, Beresini MH, Johnson A, Mintzer R, Shah K, Clark K, Schmidt S,
Lewis C, Liimatta M, Elliott LO, Gustafson A, Heise CE. Case studies of
minimizing nonspecific inhibitors in HTS campaigns that use assay-
ready plates. J Biomol Screen 2012; 17: 225–236Butler MS et al. Natural Product Libraries:… Planta Med 2014; 80: 1161–1170
1170 Review
yr
igh
te
d 
m
at
er
ial
.104 Watson J, Greenough EB, Leet JE, Ford MJ, Drexler DM, Belcastro JV,
Herbst JJ, Chatterjee M, Banks M. Extraction, identification, and func-
tional characterization of a bioactive substance from automated com-
pound-handling plastic tips. J Biomol Screen 2009; 14: 566–572
105 McDonald GR, Hudson AL, Dunn SMJ, You H, Baker GB, Whittal RM,
Martin JW, Jha A, Edmondson DE, Holt A. Bioactive contaminants leach
from disposable laboratory plasticware. Science 2008; 322: 917
106 Hermann JC, Chen Y, Wartchow C, Menke J, Gao L, Gleason SK, Haynes
NE, Scott N, Petersen A, Gabriel S, Vu B, George KM, Narayanan A, Li SH,
Qian H, Beatini N, Niu L, Gan QF.Metal impurities cause false positives
in high-throughput screening campaigns. ACS Med Chem Lett 2012;
4: 197–200
107 Marshall ICB, Owen DE, McNulty S. Measuring Ca2+ changes in multi-
well format using the Fluorometric Imaging Plate Reader (FLIPR®).
In: Lambert DG, Rainbow RD, editors. Calcium signaling protocols.
New York: Humana Press; 2013: 103–109
108 Walkup GK, Imperiali B. Fluorescent chemosensors for divalent zinc
based on zinc finger domains. Enhanced oxidative stability, metal
binding affinity, and structural and functional characterization. J Am
Chem Soc 1997; 119: 3443–3450
109 Butler MS, Yoganathan K, Buss AD, Ng S. Identification of aluminium
dioxalate in fungal cultures grown on vermiculite. J Antibiot 2012;
65: 275–276
110 Skropeta D, Pastro N, Zivanovic A. Kinase inhibitors from marine
sponges. Mar Drugs 2011; 9: 2131–2154Butler MS et al. Natural Product Libraries:… Planta Med 2014; 80: 1161–1170
op111 Cannell RJ, Kellam SJ, Owsianka AM, Walker JM. Results of a large scale
screen of microalgae for the production of protease inhibitors. Planta
Med 1988; 54: 10–14
112 Mourao CB, Schwartz EF. Protease inhibitors from marine venomous
animals and their counterparts in terrestrial venomous animals. Mar
Drugs 2013; 11: 2069–2112
113 Zhang JH, Chung TDY, Oldenburg KR. A simple statistical parameter for
use in evaluation and validation of high throughput screening assays.
J Biomol Screen 1999; 4: 67–73
114 Banks P, Harvey M. Considerations for using fluorescence polarization
in the screening of G protein-coupled receptors. J Biomol Screen
2002; 7: 111–117
115 Nielsen KF, Maansson M, Rank C, Frisvad JC, Larsen TO. Dereplication of
microbial natural products by LC‑DAD-TOFMS. J Nat Prod 2011; 74:
2338–2348
116 Gueritte F, Sevenet T, Litaudon M, Dumontet V. Biodiversity as a source
of small molecules for pharmacological screening: libraries of plant
extracts. In: Maréchal E, Roy S, Lafanechère L, editors. Chemogenom-
ics and chemical genetics: a userʼs introduction for biologists, chem-
ists and informaticians. Berlin: Springer-Verlag; 2011: 227–240
117 Koehn F. High impact technologies for natural products screening. In:
Petersen F, Amstutz R, editors. Natural compounds as drugs, Volume I.
Basel: Birkhäuser Basel; 2008: 175–210
118 Sarker SD, Nahar L. Natural products isolation, 3rd edition. New York:
Humana Press; 2012D
ow
nl
oa
de
d 
by
: I
P-
Pr
ox
y 
Un
ive
rs
ity
_Q
ue
en
sla
nd
, U
niv
er
sit
y o
f Q
ue
en
sla
nd
. C
